DaVita Inc. (NYSE:DVA) Shares Sold by Wedge Capital Management L L P NC

Wedge Capital Management L L P NC reduced its stake in DaVita Inc. (NYSE:DVA - Free Report) by 2.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 308,859 shares of the company's stock after selling 8,552 shares during the period. Wedge Capital Management L L P NC owned approximately 0.34% of DaVita worth $32,356,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of DVA. PNC Financial Services Group Inc. increased its holdings in DaVita by 1.0% in the third quarter. PNC Financial Services Group Inc. now owns 15,088 shares of the company's stock valued at $1,426,000 after buying an additional 153 shares during the last quarter. Kingswood Wealth Advisors LLC purchased a new position in DaVita in the fourth quarter valued at $2,831,000. Raymond James & Associates increased its holdings in DaVita by 135.2% in the fourth quarter. Raymond James & Associates now owns 34,376 shares of the company's stock valued at $3,601,000 after buying an additional 19,759 shares during the last quarter. Nisa Investment Advisors LLC grew its holdings in shares of DaVita by 27.8% during the fourth quarter. Nisa Investment Advisors LLC now owns 50,981 shares of the company's stock worth $5,341,000 after purchasing an additional 11,097 shares during the last quarter. Finally, Assenagon Asset Management S.A. grew its holdings in shares of DaVita by 2,178.2% during the fourth quarter. Assenagon Asset Management S.A. now owns 108,624 shares of the company's stock worth $11,379,000 after purchasing an additional 103,856 shares during the last quarter. 90.12% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at DaVita

In related news, insider Kathleen Alyce Waters sold 11,285 shares of the firm's stock in a transaction dated Wednesday, February 21st. The shares were sold at an average price of $120.73, for a total value of $1,362,438.05. Following the completion of the sale, the insider now owns 81,297 shares in the company, valued at $9,814,986.81. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, insider Kathleen Alyce Waters sold 11,285 shares of the firm's stock in a transaction dated Wednesday, February 21st. The shares were sold at an average price of $120.73, for a total value of $1,362,438.05. Following the completion of the sale, the insider now owns 81,297 shares in the company, valued at $9,814,986.81. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Javier Rodriguez sold 67,603 shares of DaVita stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $126.11, for a total transaction of $8,525,414.33. Following the sale, the chief executive officer now owns 488,697 shares of the company's stock, valued at $61,629,578.67. The disclosure for this sale can be found here. Insiders sold a total of 134,540 shares of company stock worth $16,551,071 over the last 90 days. Company insiders own 1.40% of the company's stock.

DaVita Stock Performance

Shares of NYSE DVA traded up $4.70 during midday trading on Monday, reaching $132.52. 660,110 shares of the company were exchanged, compared to its average volume of 815,753. The company has a current ratio of 1.19, a quick ratio of 1.13 and a debt-to-equity ratio of 6.65. DaVita Inc. has a 1 year low of $71.51 and a 1 year high of $141.54. The stock has a fifty day simple moving average of $131.04 and a 200 day simple moving average of $109.53. The stock has a market cap of $11.62 billion, a P/E ratio of 17.91, a PEG ratio of 1.14 and a beta of 1.04.

DaVita (NYSE:DVA - Get Free Report) last released its quarterly earnings results on Tuesday, February 13th. The company reported $1.87 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.53 by $0.34. The firm had revenue of $3.15 billion for the quarter, compared to analyst estimates of $3.01 billion. DaVita had a return on equity of 64.42% and a net margin of 5.70%. The business's revenue was up 7.8% on a year-over-year basis. During the same quarter last year, the company posted $1.11 earnings per share. On average, research analysts forecast that DaVita Inc. will post 9.23 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have issued reports on DVA. Barclays began coverage on DaVita in a report on Wednesday, March 6th. They set an "equal weight" rating and a $133.00 price objective on the stock. StockNews.com lowered DaVita from a "strong-buy" rating to a "buy" rating in a report on Tuesday, April 16th. Truist Financial raised their price objective on DaVita from $130.00 to $135.00 and gave the stock a "hold" rating in a report on Tuesday, February 20th. UBS Group raised their price objective on DaVita from $113.00 to $134.00 and gave the stock a "buy" rating in a report on Wednesday, February 14th. Finally, TheStreet raised DaVita from a "c+" rating to a "b-" rating in a report on Wednesday, February 7th. Two analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $118.50.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.